These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15119984)

  • 1. Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital.
    Rapp RP; Evans ME; Martin C; Ofotokum I; Empey KL; Armitstead JA
    Curr Med Res Opin; 2004 Apr; 20(4):469-76. PubMed ID: 15119984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital.
    Rüttimann S; Keck B; Hartmeier C; Maetzel A; Bucher HC
    Clin Infect Dis; 2004 Feb; 38(3):348-56. PubMed ID: 14727204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
    Enzweiler KA; Bosso JA; White RL
    Pharmacotherapy; 2003 Jul; 23(7):925-32. PubMed ID: 12885105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulary management: antibiotics and therapeutic interchange.
    Massoomi F
    Pharm Pract Manag Q; 1996 Oct; 16(3):11-8. PubMed ID: 10166231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a selective restriction policy on antibiotic expenditure and use: an institutional model.
    Suwangool P; Moola-Or P; Waiwatana A; Sitthi-Amorn C; Israsena S; Hanvanich M
    J Med Assoc Thai; 1991 Jul; 74(7):272-5. PubMed ID: 1765742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing an automatic fluoroquinolone therapeutic interchange program in a community hospital.
    Mioduch HJ
    Hosp Formul; 1992 Sep; 27(9):943-4, 947. PubMed ID: 10128743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility.
    Rifenburg RP; Paladino JA; Bhavnani SM; Haese DD; Schentag JJ
    Am J Health Syst Pharm; 1999 Nov; 56(21):2217-23. PubMed ID: 10565701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.
    Bhavnani SM; Callen WA; Forrest A; Gilliland KK; Collins DA; Paladino JA; Schentag JJ
    Am J Health Syst Pharm; 2003 Oct; 60(19):1962-70. PubMed ID: 14531241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an antibiotic intravenous to oral sequential therapy program.
    Pablos AI; Escobar I; Albiñana S; Serrano O; Ferrari JM; Herreros de Tejada A
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):53-9. PubMed ID: 15534901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
    Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
    Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and quality considerations in antibiotic formulary management.
    Ritchie DF
    Pharm Pract Manag Q; 1996 Jul; 16(2):4-8. PubMed ID: 10161610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong.
    Ng CK; Wu TC; Chan WM; Leung YS; Li CK; Tsang DN; Leung GM
    Qual Saf Health Care; 2008 Oct; 17(5):387-92. PubMed ID: 18842981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
    Bhavnani SM; Hammel JP; Jones RN; Ambrose PG
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):31-7. PubMed ID: 15629226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial formulary management: meeting the challenge in the community hospital.
    Rush DR
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):19S-26S. PubMed ID: 2011569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.